These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19326961)

  • 41. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab.
    Easthope S; Jarvis B
    Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Omralizumab (Xolair) in severe persistent allergic asthma].
    Schleich F; Manise M; Louis R
    Rev Med Liege; 2009; 64(5-6):313-7. PubMed ID: 19642466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
    Holgate S; Buhl R; Bousquet J; Smith N; Panahloo Z; Jimenez P
    Respir Med; 2009 Aug; 103(8):1098-113. PubMed ID: 19362459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor necrosis factor-alpha: a promising therapeutic target for asthma?
    Heffler E; Berry M; Pavord ID
    BioDrugs; 2007; 21(6):345-9. PubMed ID: 18020618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Omalizumab in severe asthma--case report].
    Gawlewicz-Mroczka A; Nizankowska-Mogilnicka E
    Pol Arch Med Wewn; 2006 Aug; 116(2):766-70. PubMed ID: 17424922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of monoclonal antibodies and related agents in the treatment of respiratory disease.
    Schachter EN; Neuman T
    Drugs Today (Barc); 2009 Jul; 45(7):533-48. PubMed ID: 19834630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Xolair in asthma therapy: an overview.
    Di Domenico M; Bisogno A; Polverino M; De Rosa C; Ricci V; Capasso A
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):2-12. PubMed ID: 21184647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.
    Walters EH; Walters JA; Wood-Baker R
    Expert Opin Pharmacother; 2007 Apr; 8(5):585-92. PubMed ID: 17376014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
    Asai N; Ohkuni Y; Komatsu A; Matsunuma R; Nakashima K; Kaneko N
    J Bras Pneumol; 2011; 37(4):567-70. PubMed ID: 21881749
    [No Abstract]   [Full Text] [Related]  

  • 56. Discrimination against children with severe allergies.
    Warner JO
    Pediatr Allergy Immunol; 2008 Dec; 19(8):671-2. PubMed ID: 19076563
    [No Abstract]   [Full Text] [Related]  

  • 57. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Innovative therapies for asthma: anti-IgE -- the future?
    Weinberger M
    Paediatr Respir Rev; 2004; 5 Suppl A():S115-8. PubMed ID: 14980255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.